Migration, psychosis and immune activatio

• Conditions: psychosis; schizophrenia; 10039628

• Registration Number: NL-OMON35853
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

Patients:
Group 1. 15 participants, born in or born from parents born in Morocco, Turkey, Surinam or the Netherlands Antilles, age at migration < 5 years for first generation immigrants, current age 18-40, diagnosis of DSM IV schizophrenia, schizoaffective disorder or schizophreniform disorder, use of antipsychotic medication for less than two years.
Group 2. Contrast patients: 15 participants, born in the Netherlands and both parents born in the Netherlands, other inclusion criteria as in group 1.;Controls:
Exposed controls: 15 participants, born in or born from parents born in Morocco, Turkey, Surinam or the Netherlands Antilles, age at migration < 5 years for first generation immigrants, current age 18-40, no history of psychotic disorder. Unexposed controls: 15 participants, born in the Netherlands and both parents born in the Netherlands, age 18-40, no history of psychotic disorder.

Exclusion Criteria

Patients:
Diagnosis of DSM IV substance induced psychotic disorder, mood disorder with psychotic features, delusional disorder, psychotic disorder NOS or psychotic disorder due to a somatic condition; IQ lower than 70.;Controls:
History of psychotic disorder; IQ lower than 70.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Mean level of mRNA in monocytes and intracellular cytokines in T-cells.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>